Literature DB >> 16210414

Daily, intermittent intravenous infusion of peptide YY(3-36) reduces daily food intake and adiposity in rats.

Prasanth K Chelikani1, Alvin C Haver, Joseph R Reeve, David A Keire, Roger D Reidelberger.   

Abstract

The gut hormone peptide YY(3-36) [PYY(3-36)] decreases food intake when administered by intravenous infusion to lean and obese humans and rats. Whether chronic administration of PYY(3-36) produces a sustained reduction in food intake and adiposity is the subject of intense debate. Batterham et al. (R. L. Batterham, M. A. Cowley, C. J. Small, H. Herzog, M. A. Cohen, C. L. Dakin, A. M. Wren, A. E. Brynes, M. J. Low, M. A. Ghatei, R. D. Cone, and S. R. Bloom. Nature 418: 650-654, 2002) first reported that PYY(3-36) reduces food intake and weight gain in rats when injected into the peritoneal cavity twice daily for 7 days. Numerous laboratories have failed to confirm that daily injections of PYY(3-36) decrease body weight. Continuous subcutaneous administration of PYY(3-36) by osmotic minipump has been reported to reduce daily food intake in rodents but only during the first 3-4 days of administration. Here we show the effects of different daily patterns of intravenous infusion of PYY(3-36) on food intake, body weight, and adiposity in rats tethered via infusion swivels to computer-controlled pumps. Measurement of food bowl weight recorded by computer every 20 s permitted daily assessment of the instantaneous effects of PYY(3-36) administration on food intake and meal patterns. One-hour intravenous infusions of PYY(3-36) at 30 pmol x kg(-1) x min(-1) every other hour for 10 days produced a sustained reduction in daily food intake of approximately 20% and decreased body weight and adiposity by 7 and 35%, respectively. Thus dosage pattern is critical for producing a sustained effect of PYY(3-36) on food intake and adiposity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210414     DOI: 10.1152/ajpregu.00674.2005

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  38 in total

1.  Mesoporous silicon (PSi) for sustained peptide delivery: effect of psi microparticle surface chemistry on peptide YY3-36 release.

Authors:  Miia Kovalainen; Juha Mönkäre; Ermei Mäkilä; Jarno Salonen; Vesa-Pekka Lehto; Karl-Heinz Herzig; Kristiina Järvinen
Journal:  Pharm Res       Date:  2011-10-27       Impact factor: 4.200

Review 2.  Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin.

Authors:  Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye
Journal:  Mol Cell Endocrinol       Date:  2018-11-02       Impact factor: 4.102

3.  Strategies for preventing type 2 diabetes: an update for clinicians.

Authors:  Kaivan Khavandi; Halima Amer; Bashar Ibrahim; Jack Brownrigg
Journal:  Ther Adv Chronic Dis       Date:  2013-09       Impact factor: 5.091

Review 4.  Gastrointestinal regulation of food intake.

Authors:  David E Cummings; Joost Overduin
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

Review 5.  Eating for pleasure or calories.

Authors:  Huiyuan Zheng; Hans-Rudolf Berthoud
Journal:  Curr Opin Pharmacol       Date:  2007-11-26       Impact factor: 5.547

Review 6.  Neuropeptide Y Y2 receptor in health and disease.

Authors:  S L Parker; A Balasubramaniam
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 7.  Gut hormones as potential new targets for appetite regulation and the treatment of obesity.

Authors:  Benjamin C T Field; Alison M Wren; Dunstan Cooke; Stephen R Bloom
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Vagal and hormonal gut-brain communication: from satiation to satisfaction.

Authors:  H-R Berthoud
Journal:  Neurogastroenterol Motil       Date:  2008-05       Impact factor: 3.598

Review 9.  Obesity treatment: novel peripheral targets.

Authors:  Benjamin C T Field; Owais B Chaudhri; Stephen R Bloom
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

10.  GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents.

Authors:  Jianping Ye; Zheng Hao; Michael B Mumphrey; R Leigh Townsend; Laurel M Patterson; Nicholas Stylopoulos; Heike Münzberg; Christopher D Morrison; Daniel J Drucker; Hans-Rudolf Berthoud
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-01-15       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.